Clinical Trial Update: Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AFP + GM-CSF plasmid prime followed by an AFP adenoviral vector boost in hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AFP + GM-CSF plasmid prime
• AFP adenoviral vector boost

Snippet

Sponsor: Lisa H. Butterfield, Ph.D. | Conditions: Hepatocellular Carcinoma, Hepatoma | Phase 1 | Status: TERMINATED